A
Arnab Mukherjee
Researcher at University of Tennessee Health Science Center
Publications - 13
Citations - 856
Arnab Mukherjee is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Androgen receptor & Prostate cancer. The author has an hindex of 11, co-authored 13 publications receiving 836 citations. Previous affiliations of Arnab Mukherjee include University of Tennessee & Xavier University of Louisiana.
Papers
More filters
Journal ArticleDOI
Discovery of Nonsteroidal Androgens
TL;DR: These ligands represent the first members of a novel class of androgens with potential therapeutic applications in male fertility and hormone replacement therapy and demonstrate that nonsteroidal ligands can be structurally modified to produce agonist activity.
Journal ArticleDOI
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.
Craig A. Marhefka,Bob M. Moore,Thomas C. Bishop,Leonid I. Kirkovsky,Arnab Mukherjee,James T. Dalton,Duane D. Miller +6 more
TL;DR: Docking studies indicate that Asn705 is an important determinant in binding hydroxyflutamide and its derivatives by participating in H-bond interactions with the alpha-hydroxy moiety of these ligands, and a mechanism for the enantioselective binding of chiral hydroxyFLutamide derivatives is suggested.
Journal ArticleDOI
Enantioselective binding of Casodex to the androgen receptor
TL;DR: This study demonstrated that (R)-Casodex has a higher binding affinity than its stereoisomer and suggests that the antiandrogenic activity of racemic Casodex is almost completely due to the (R-isomer).
Journal ArticleDOI
Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring.
TL;DR: Overall, the para-substituted unoxidized molecules demonstrated the highest AR binding affinity, and the isothiocyanate affinity ligands reported herein are the first specific chemoaffinity ligands for the AR.
Patent
Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
TL;DR: In this paper, non-steroidal radiolabeled androgen receptor ligands and their use in methods of imaging the prostate were described and discussed. But their use was limited to prostate cancer detection.